{
  "ticker": "JNJ",
  "target_date": "2025-02-25",
  "actual_date": "2025-02-25",
  "collected_at": "2025-12-08T11:26:48.927651",
  "price": {
    "open": 160.5,
    "high": 162.78,
    "low": 160.34,
    "close": 162.44688415527344,
    "volume": 12303700,
    "change_1d_pct": 1.44,
    "change_7d_pct": 6.47,
    "change_30d_pct": 17.85
  },
  "technicals": {
    "rsi_14": 83.15,
    "sma_20": 151.59,
    "sma_50": 145.31,
    "macd": 3.942,
    "macd_signal": 2.869,
    "macd_histogram": 1.073,
    "bb_upper": 160.8,
    "bb_lower": 142.38,
    "price_vs_sma20_pct": 7.16,
    "price_vs_sma50_pct": 11.79,
    "volume_ratio": 1.42
  },
  "fundamentals": {
    "market_cap": 488894169088,
    "pe_ratio": 19.586874,
    "forward_pe": 19.143394,
    "price_to_book": 6.1589828,
    "price_to_sales": 5.3054748,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.35,
    "pct_from_52w_low": 44.24
  },
  "macro": {
    "spy": {
      "price": 589.08,
      "change_1d_pct": -0.5,
      "change_7d_pct": -2.54
    },
    "vix": {
      "level": 19.43,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.3
    },
    "dollar_index": {
      "level": 106.31
    },
    "gold": {
      "price": 2904.5
    },
    "regime": "BEAR_NORMAL"
  },
  "news": [
    {
      "headline": "J&J sues Samsung Bioepis over \u2018surreptitious\u2019 breach of Stelara biosimilar contract",
      "source": "Yahoo",
      "datetime": 1740526952,
      "summary": "Samsung Bioepis has allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous settlement.",
      "url": "https://finnhub.io/api/news?id=10ed8923d37fce488cb0faa329b20d8bd88acbe9afc466657528b6b67babc328"
    },
    {
      "headline": "Johnson & Johnson (JNJ) Ascends While Market Falls: Some Facts to Note",
      "source": "Yahoo",
      "datetime": 1740523531,
      "summary": "In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $166.09, denoting a +1.44% change from the preceding trading day.",
      "url": "https://finnhub.io/api/news?id=3f83e663933ff7d03d3933d2e3b6908e95d4fa21178297b823b4eb2226557eb3"
    },
    {
      "headline": "Healthcare Stocks Should Be Hurting. How the Sector Became This Year\u2019s Top Performer.",
      "source": "MarketWatch",
      "datetime": 1740500160,
      "summary": "Healthcare Stocks Should Be Hurting. How the Sector Became This Year\u2019s Top Performer.",
      "url": "https://finnhub.io/api/news?id=8833f98acfa862636e1dce43c993c99937aee464d76cc2b2afdacba07a93c573"
    },
    {
      "headline": "Johnson & Johnson (JNJ) Ranked 4th Best S&P 500 Dividend Aristocrat According to Hedge Funds",
      "source": "Yahoo",
      "datetime": 1740494627,
      "summary": "We recently published a list of S&P 500 Dividend Aristocrats List: Sorted By Hedge Fund Sentiment. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other S&P 500 dividend aristocrats sorted by hedge fund sentiment. Dividend Aristocrats are companies t",
      "url": "https://finnhub.io/api/news?id=8c534c0835c136112dc2b59598a3522e576b92a60d389c1584884859a4ec0dc4"
    },
    {
      "headline": "J&J\u2019s potential neurovascular exit: implications for market dynamics",
      "source": "Yahoo",
      "datetime": 1740483536,
      "summary": "The neurovascular market, estimated at $4.2bn in 2024 by GlobalData, is becoming increasingly specialised and competitive.",
      "url": "https://finnhub.io/api/news?id=3a2b3db73f08d02fb1f17a999c21bb091a5230c03a844a6ddac2e6218a1fe0ea"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "8-K",
      "date": "2025-02-20",
      "description": "d866332d8k.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000119312525030851/d866332d8k.htm"
    },
    {
      "form": "4",
      "date": "2025-02-19",
      "description": "xslF345X05/wk-form4_1740005083.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000084/xslF345X05/wk-form4_1740005083.xml"
    },
    {
      "form": "4",
      "date": "2025-02-19",
      "description": "xslF345X05/wk-form4_1740004664.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000082/xslF345X05/wk-form4_1740004664.xml"
    },
    {
      "form": "4",
      "date": "2025-02-19",
      "description": "xslF345X05/wk-form4_1740004513.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000080/xslF345X05/wk-form4_1740004513.xml"
    },
    {
      "form": "4",
      "date": "2025-02-19",
      "description": "xslF345X05/wk-form4_1740004392.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000078/xslF345X05/wk-form4_1740004392.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}